SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-091494
Filing Date
2023-08-14
Accepted
2023-08-14 17:10:21
Documents
17
Period of Report
2023-08-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2323641d2_8k.htm   iXBRL 8-K 32467
2 EXHIBIT 1.1 tm2323641d2_ex1-1.htm EX-1.1 225418
3 EXHIBIT 5.1 tm2323641d2_ex5-1.htm EX-5.1 12617
8 GRAPHIC tm2323641d2_ex5-1img001.jpg GRAPHIC 3904
9 GRAPHIC tm2323641d2_ex5-1img002.jpg GRAPHIC 1603
  Complete submission text file 0001104659-23-091494.txt   552054

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20230814.xsd EX-101.SCH 3303
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20230814_def.xml EX-101.DEF 26897
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20230814_lab.xml EX-101.LAB 36508
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20230814_pre.xml EX-101.PRE 25521
11 EXTRACTED XBRL INSTANCE DOCUMENT tm2323641d2_8k_htm.xml XML 4906
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 231171886
SIC: 2834 Pharmaceutical Preparations